Stock · AUROPHARMA · Healthcare
AUROPHARMA share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for AUROBINDO PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on AUROBINDO PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads AUROPHARMA as constructive with a Crack Score of 93/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where AUROPHARMA stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
50/100Money flow
50/100Result pulse · Q4 FY26
50/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
Red flags
above 200DMA (not a confirmed short-side trend)
Relative valuation
P/E (TTM)
26.2P/E vs sector
+0.5%Sector percentile
9PEG
13.17Scanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for AUROPHARMA are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the AUROPHARMA chart, refreshed every end-of-day run.
The Crack Score, and how it is built93 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for AUROPHARMA, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on AUROPHARMA reads right now.
The editorial price read on AUROPHARMA is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on AUROPHARMA can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving AUROPHARMA.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why AUROPHARMA moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
AUROBINDO PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
50 / 100Revenue
Rs 8,853 crNet profit
Rs 921 crEPS (quarter)
Rs 15.86| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +5.6% | +2.4% |
| Net profit | +2.0% | +1.2% |
| Net margin | +10.4% | |
Figures are the Q4 FY26 result for AUROBINDO PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
AUROBINDO PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
AUROPHARMA official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 8,853 cr | Rs 15.86 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 8,646 cr | Rs 15.67 | n/a | 50/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 8,286 cr | Rs 14.61 | n/a | 50/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 7,868 cr | Rs 14.20 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 8,382 cr | Rs 15.56 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 7,979 cr | Rs 14.56 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 7,796 cr | Rs 14.00 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 7,567 cr | Rs 15.69 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 7,580 cr | Rs 15.51 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 7,352 cr | Rs 16.04 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 7,219 cr | Rs 12.83 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 6,851 cr | Rs 9.74 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 6,473 cr | Rs 8.64 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 6,407 cr | Rs 8.38 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 5,739 cr | Rs 6.99 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 6,236 cr | Rs 8.88 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 5,809 cr | Rs 9.84 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 6,002 cr | Rs 10.32 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 5,942 cr | Rs 11.89 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 5,702 cr | Rs 13.14 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 6,002 cr | Rs 13.67 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 6,365 cr | Rs 50.29 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 6,483 cr | Rs 13.75 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 5,925 cr | Rs 13.32 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 6,158 cr | Rs 14.50 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 5,895 cr | Rs 12.04 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 5,600 cr | Rs 10.92 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 5,445 cr | Rs 10.85 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 5,292 cr | Rs 9.99 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 5,270 cr | Rs 12.15 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 4,751 cr | Rs 10.44 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 4,250 cr | Rs 7.78 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
AUROBINDO PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
33,653 crNet profit (TTM)
3,503 crEBIT (TTM)
5,494 crProfit before tax (TTM)
5,110 crNet margin (TTM)
10.4%Finance costs (TTM)
384 crBalance sheet, as filed 2026-03-31
Total assets
58,502 crShareholder equity
37,883 crTotal borrowings
7,676 crCash and equivalents
7,191 crInventory
12,053 crTrade receivables
7,094 crThe cash engine, latest filed year
Operating cash flow
5,526 crCapex
3,105 crFree cash flow
2,422 crInvesting flow
-3,458 crFinancing flow
-1,269 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 33,653 cr | 3,503 cr | 37,883 cr | 7,676 cr | 5,526 cr |
| FY25 | 31,724 cr | 3,484 cr | 32,647 cr | 7,942 cr | 3,925 cr |
| FY24 | 29,002 cr | 3,169 cr | 29,851 cr | 6,315 cr | 2,435 cr |
| FY23 | 24,855 cr | 1,928 cr | 26,852 cr | 4,862 cr | 2,387 cr |
| FY22 | 23,455 cr | 2,647 cr | 24,574 cr | 2,373 cr | 5,016 cr |
| FY21 | 24,775 cr | 5,334 cr | 21,929 cr | 4,971 cr | n/a |
Every figure is parsed from AUROBINDO PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record29 earnings calls
Every AUROPHARMA earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
AUROBINDO PHARMA LIMITED earnings calls on record
29 calls since 30 Jun 2019
Show 21 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from AUROBINDO PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
AUROBINDO PHARMA LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of AUROBINDO PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the AUROPHARMA chart. Not a substitute for a registered research note.
| Ticker | AUROPHARMA |
|---|---|
| Full name | AUROBINDO PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE406A01037 |
| Market-cap band | ~91,718 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | AUROPHARMA |
Reference chartLevels in show
The daily frame the desk reads on AUROPHARMA.
FAQ11 reader questions · AEO-eligible
The line on AUROPHARMA, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the AUROPHARMA share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on AUROPHARMA. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for AUROPHARMA?
The BazaarBaazi Crack Score for AUROPHARMA is 93 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on AUROPHARMA?
Strike-level option inventory for AUROPHARMA is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is AUROPHARMA in and which peers does BazaarBaazi track?
AUROPHARMA sits in Healthcare (mid cap), indicative market cap ~91,718 cr (indicative), ISIN INE406A01037. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on AUROBINDO PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the AUROPHARMA view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on AUROPHARMA is bullish, published in Systematic Read on 21 Jul 2026.
Is AUROPHARMA a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, AUROBINDO PHARMA LIMITED sits in the Scanned tier with a setup score of 71/100 (technical 100, fundamental 50). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read AUROBINDO PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 29 AUROPHARMA earnings calls going back to 2019-06-30, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was AUROBINDO PHARMA LIMITED's Q4 FY26 net profit?
AUROBINDO PHARMA LIMITED reported a net profit of Rs 921 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +2.0% year on year. The figure is from the company's official NSE filing.
What was AUROBINDO PHARMA LIMITED's Q4 FY26 revenue?
AUROBINDO PHARMA LIMITED reported revenue of Rs 8,853 cr for Q4 FY26. That is +5.6% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate AUROBINDO PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives AUROBINDO PHARMA LIMITED's Q4 FY26 result a Result Pulse of 50 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Aurobindo Pharma Ltd announced recently?
The most recent official filing on record for Aurobindo Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside AUROPHARMA, each a living view refreshed every end-of-day run.